$85.76
4.14% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US8342032005
Symbol
SLNO

Soleno Therapeutics Inc Stock price

$85.76
+4.20 5.14% 1M
+36.36 73.60% 6M
+40.81 90.79% YTD
+38.92 83.09% 1Y
+82.84 2,831.97% 3Y
+57.26 200.91% 5Y
-46.24 35.03% 10Y
-205.24 70.53% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+3.41 4.14%
ISIN
US8342032005
Symbol
SLNO
Industry

Key metrics

Basic
Market capitalization
$4.6b
Enterprise Value
$4.3b
Net debt
positive
Cash
$286.8m
Shares outstanding
50.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
139.6 | 39.3
EV/Sales
132.3 | 37.1
EV/FCF
negative
P/B
19.0
Financial Health
Equity Ratio
74.1%
Return on Equity
-71.7%
ROCE
-61.5%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$32.7m | $111.5m
EBITDA
$-189.6m | -
EBIT
$-191.6m | $-98.4m
Net Income
$-181.1m | $-161.6m
Free Cash Flow
$-84.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-169.6% | -
EBIT
-165.0% | 47.6%
Net Income
-177.9% | 8.1%
Free Cash Flow
-98.4%
Margin (TTM | estimate)
Gross
97.9%
EBITDA
-580.5% | -
EBIT
-586.7%
Net
-554.5% | -145.0%
Free Cash Flow
-259.3%
More
EPS
$-3.6
FCF per Share
$-1.7
Short interest
12.7%
Employees
92
Rev per Employee
$0.0
Show more

Is Soleno Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Soleno Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Soleno Therapeutics Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Soleno Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Soleno Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
33 33
-
100%
- Direct Costs 0.70 0.70
-
2%
32 32
-
98%
- Selling and Administrative Expenses 144 144
435% 435%
441%
- Research and Development Expense 74 74
78% 78%
227%
-190 -190
170% 170%
-580%
- Depreciation and Amortization 2.01 2.01
3% 3%
6%
EBIT (Operating Income) EBIT -192 -192
165% 165%
-587%
Net Profit -181 -181
178% 178%
-554%

In millions USD.

Don't miss a Thing! We will send you all news about Soleno Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Soleno Therapeutics Inc Stock News

Neutral
Seeking Alpha
5 days ago
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James H. MacKaness - CFO & Compliance Officer Meredith Manning - Chief Commercial Officer Conference Call Participants Brian Peter Skorney - Robert W.
Positive
The Motley Fool
5 days ago
Soleno (SLNO) Q2 Revenue Jumps 30%
Neutral
GlobeNewsWire
6 days ago
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025.
More Soleno Therapeutics Inc News

Company Profile

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Head office United States
CEO Anish Bhatnagar
Employees 92
Founded 1999
Website soleno.life

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today